Healthcare Triangle Launches Neurotechnology AI Devices and Solutions for Southeast Asia

Asia PacificDigital HealthProducts & Technologies

Healthcare Triangle has announced the launch of Neurotechnology AI Devices Sales and Solutions through its wholly owned Malaysia-based subsidiary, Quantum Nexis, with strategic healthcare, wellness, neuroscience, and public-sector initiatives being pursued across Southeast Asia. Malaysia and Indonesia form the initial focus of the initiative, combining neuroscience devices, professional education, and AI-supported mental healthcare.

As healthcare systems shift toward preventive care, mental resilience, longevity, cognitive performance, and wellness outcomes, Quantum Nexis is building a foundation to bring brain mapping and neurotechnology capabilities to healthcare organizations, wellness centers, hospitality groups, enterprises, and government-aligned initiatives throughout Malaysia and Indonesia. The program encompasses device manufacturing development, clinical technology integration, and professional education, with the aim of helping practitioners translate advances in brain science into practical applications for mental health treatment, rehabilitation, and cognitive wellbeing.

The initiative is structured around three revenue streams: neurotechnology device sales and servicing; professional training and certification through a Quantum Nexis academy; and recurring AI-enabled software subscriptions for clinics. The clinical software layer draws on Healthcare Triangle’s existing cloud, data, and AI capabilities. The development roadmap includes EEG and quantitative EEG tools for recording and analyzing brain electrical activity; neurofeedback and physiological biofeedback systems; and non-invasive brain stimulation technologies including transcranial electrical stimulation and repetitive transcranial magnetic stimulation. A core strategic objective is to develop manufacturing capability in Malaysia through a phased pathway covering device integration, assembly, software configuration, testing, calibration, quality assurance, and technical support, with first regulatory submission to Malaysia’s Medical Device Authority targeted for the first quarter of 2027 and first locally assembled devices targeted for the third quarter of 2027.

AI development will focus on helping professionals organize and interpret complex information across clinical assessments, cognitive measures, physiological recordings, and treatment progress, with potential applications including signal quality review, pattern identification for further clinical investigation, documentation support, and tracking changes over time. The company noted that clinical judgment, patient consent, and professional accountability will remain central, and that AI-supported outputs will require appropriate validation, protection of sensitive information, and assessment of suitability for local populations.

The company cited market data showing the global neurotech devices market is projected to grow from $15.2 billion in 2024 to $30.3 billion by 2030, a compound annual growth rate of 12.2%, with Asia-Pacific the fastest-growing region for mental health technology at a projected 13.2% annual growth rate from 2024 to 2030. In Malaysia, around one million people aged over 15, or 4.6% of that population, live with depression, double the number recorded in 2019, according to the Ministry of Health’s National Health and Morbidity Survey 2023, while in Indonesia only 10.4% of young people aged 15 to 24 with depression seek treatment, according to the Ministry of Health’s 2023 Indonesian Health Survey.

Ehsan Masoumi, Director of Quantum Nexis, said making neurotechnology accessible requires more than supplying equipment, and that professionals need the knowledge to interpret the information, select appropriate interventions, and understand the limits of each technology. Masoumi noted that the vision is to develop regional capability across devices, software, education, and clinical practice so that advances in neuroscience can contribute meaningfully to people’s mental health and everyday functioning.